INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • 10 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GlobeNewsWire • Oct 13, 2026

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.

GlobeNewsWire • Oct 13, 2026

Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse

Short sellers are betting heavily against 10 stocks, and the fuse is getting shorter. Each one has more than 38% of its float sold short, with market caps above $2 billion and average daily volume above 1 million shares, according to Benzinga Pro screener data as of Oct. 12.

Benzinga • Oct 13, 2026

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress

Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers first-mover advantage, while Risto-cel's blockbuster potential is now downgraded. AI-driven competition, such as Anthropic, is unlikely to disrupt BEAM in the near term; partnerships with AI firms could become a future catalyst.

Seeking Alpha • Sep 29, 2026

Squeeze Watch: 10 Stocks With Over 33% Short Interest

Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.

Benzinga • Sep 25, 2026

BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $BEAM--BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law.

Business Wire • Sep 16, 2026

These 10 Stocks Are Squeeze Candidates Waiting to Happen

Short sellers are making bold bets, and the numbers behind those bets are getting harder to ignore. Pessimism this concentrated can set the stage for sharp reversals, since a heavily shorted stock only needs a piece of good news to send bears scrambling to cover their positions.

Benzinga • Sep 14, 2026

Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha • Sep 9, 2026

Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment

Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD).

Benzinga • Sep 8, 2026